Todd C. Davis - 05 Dec 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Todd C. Davis
Issuer symbol
LGND
Transactions as of
05 Dec 2022
Net transactions value
$0
Form type
4
Filing time
06 Dec 2022, 19:25:57 UTC
Previous filing
08 Aug 2022
Next filing
27 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Award $0 +132,000 $0.000000 132,000 05 Dec 2022 Common Stock 132,000 $69.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from the date of grant, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after the date of grant and the remaining stock options vesting in 42 equal monthly installments thereafter.